Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Earnings
Neximmune reports Q1 EPS (66c), consensus (70c) » 16:11
05/12/22
05/12
16:11
05/12/22
16:11
NEXI

Neximmune

$2.07 /

-0.055 (-2.59%)

Cash, cash equivalents…

Cash, cash equivalents and marketable securities for the Company as of March 31, 2022 were $65.0 million compared to $81.8 million for quarter ending December 31, 2021. Based upon current operating plans, NexImmune expects that its existing cash, cash equivalents and marketable securities will enable the Company to fund its operating and capital expenditure requirements into the second quarter of 2023. "This quarter, we have continued to execute on our clinical and corporate strategy, taking the necessary steps to achieve our upcoming catalysts for the remainder of this year," said Kristi Jones, Chief Executive Officer. "We remain on track to provide a clinical update for the NEXI-001 trial in AML during the second half of 2022, and to provide an update on the expansion cohort in the NEXI-002 trial in relapsed / refractory multiple myeloma. We also plan to file our first solid tumor IND application for HPV-associated malignancies in the near term. In parallel, we are advancing IND-enabling work for our AIM injectable modality and expect to provide updates on preclinical data for oncology and autoimmune indications throughout the second half of the year. With our new target discovery collaborations, we are well-positioned to leverage our modular AIM platform for efficient and rapid new product development. Overall, I am excited with our progress and focus on execution to deliver on upcoming catalysts."

ShowHide Related Items >><<
NEXI Neximmune
$2.07 /

-0.055 (-2.59%)

NEXI Neximmune
$2.07 /

-0.055 (-2.59%)

04/01/22 Barclays
Neximmune price target raised to $7 from $4 at Barclays
11/15/21 Raymond James
Neximmune price target lowered to $21 from $30 at Raymond James
NEXI Neximmune
$2.07 /

-0.055 (-2.59%)

Hot Stocks
Neximmune appoints Gandhi to board of directors » 07:53
05/10/22
05/10
07:53
05/10/22
07:53
NEXI

Neximmune

$2.62 /

-0.33 (-11.19%)

NexImmune announced the…

NexImmune announced the appointment of Leena Gandhi, M.D., Ph.D., Director for the Center of Therapeutic Innovation at Dana-Farber Cancer Institute, to its Board of Directors as a Non-Executive Director.

ShowHide Related Items >><<
NEXI Neximmune
$2.62 /

-0.33 (-11.19%)

NEXI Neximmune
$2.62 /

-0.33 (-11.19%)

04/01/22 Barclays
Neximmune price target raised to $7 from $4 at Barclays
11/15/21 Raymond James
Neximmune price target lowered to $21 from $30 at Raymond James
NEXI Neximmune
$2.62 /

-0.33 (-11.19%)

Over a month ago
Hot Stocks
Neximmune announces preclinical research collaboration with CUIMC's HICCC » 07:36
04/26/22
04/26
07:36
04/26/22
07:36
NEXI

Neximmune

$2.64 /

+ (+0.00%)

NexImmune announced a…

NexImmune announced a preclinical research collaboration with Columbia University Irving Medical Center's, CUIMC, Herbert Irving Comprehensive Cancer Center, HICCC. The research will focus on the use of NexImmune's adoptive cell therapy, AIM ACT, in Columbia's patient-derived organoid, PDO, models of HPV-associated cancers, including head and neck squamous cell carcinoma. "HPV-associated cancers remain an area with a large unmet medical need," said Dr. Jerry Zeldis, Executive Vice President, R&D of NexImmune. "Our collaboration with Columbia University Irving Medical Center will continue to help us develop new therapies for those patients that are not adequately treated and cured with existing standard of care."

ShowHide Related Items >><<
NEXI Neximmune
$2.64 /

+ (+0.00%)

NEXI Neximmune
$2.64 /

+ (+0.00%)

04/01/22 Barclays
Neximmune price target raised to $7 from $4 at Barclays
11/15/21 Raymond James
Neximmune price target lowered to $21 from $30 at Raymond James
NEXI Neximmune
$2.64 /

+ (+0.00%)

Hot Stocks
Neximmune promotes Mathias Oelke to Chief Scientific Officer » 16:03
04/14/22
04/14
16:03
04/14/22
16:03
NEXI

Neximmune

$2.87 /

-0.03 (-1.03%)

NexImmune has promoted…

NexImmune has promoted Mathias Oelke to Chief Scientific Officer. Oelke is a scientific co-founder of NexImmune and joined NexImmune in 2014. Prior to his promotion, he served as Senior VP, Preclinical Immunotherapy and Head of Cell Biology of NexImmune since 2017.

ShowHide Related Items >><<
NEXI Neximmune
$2.87 /

-0.03 (-1.03%)

NEXI Neximmune
$2.87 /

-0.03 (-1.03%)

04/01/22 Barclays
Neximmune price target raised to $7 from $4 at Barclays
11/15/21 Raymond James
Neximmune price target lowered to $21 from $30 at Raymond James
NEXI Neximmune
$2.87 /

-0.03 (-1.03%)

Recommendations
Neximmune price target raised to $7 from $4 at Barclays » 07:10
04/01/22
04/01
07:10
04/01/22
07:10
NEXI

Neximmune

$4.23 /

+0.37 (+9.59%)

Barclays analyst Peter…

Barclays analyst Peter Lawson raised the firm's price target on Neximmune to $7 from $4 and keeps an Overweight rating on the shares. The analyst is "incrementally positive" on NexImmune's platform after a call with Dr. Ran Reshef to discuss emerging therapies in multiple myeloma.

ShowHide Related Items >><<
NEXI Neximmune
$4.23 /

+0.37 (+9.59%)

NEXI Neximmune
$4.23 /

+0.37 (+9.59%)

11/15/21 Raymond James
Neximmune price target lowered to $21 from $30 at Raymond James
NEXI Neximmune
$4.23 /

+0.37 (+9.59%)

Hot Stocks
Neximmune up 10% after Verstandig buys $750K in shares » 09:58
03/29/22
03/29
09:58
03/29/22
09:58
NEXI

Neximmune

$3.60 /

+0.35 (+10.77%)

Shares of Neximmune are…

Shares of Neximmune are up 32c, or 10%, to $3.56 in early trading after a regulatory filing last night showed that director Grant Verstandig bought 190,600 shares in purchase made between March 24 and March 28 with a total transaction value of about $750,000. Reference Link

ShowHide Related Items >><<
NEXI Neximmune
$3.60 /

+0.35 (+10.77%)

NEXI Neximmune
$3.60 /

+0.35 (+10.77%)

11/15/21 Raymond James
Neximmune price target lowered to $21 from $30 at Raymond James
03/31/21 Raymond James
Neximmune initiated with an Outperform at Raymond James
NEXI Neximmune
$3.60 /

+0.35 (+10.77%)

Hot Stocks
Neximmune, Zephyr AI announce strategic partnership in oncology » 07:35
03/17/22
03/17
07:35
03/17/22
07:35
NEXI

Neximmune

$1.80 /

-0.12 (-6.25%)

NexImmune announced a…

NexImmune announced a strategic partnership focusing on the discovery and validation of novel targets for new T-cell-mediated therapies in oncology. Combining Zephyr's proprietary artificial intelligence and algorithmic technology with NexImmune's Artificial Immune Modulation, AIM, nanoparticle technology, the collaboration will seek to identify and validate optimal antigens and antigen cocktails for the development of potential new therapeutics in solid and hematological cancers. Under the terms of the agreement, Zephyr will employ its AI and machine learning technology to identify targets suitable for activating T-cell-mediated anti-tumor responses. Specifically, Zephyr will evaluate a range of molecular and genetic data through in silico target discovery to uncover known, high potential tumor-associated antigens and neoantigens that map to specific subtypes of cancer. NexImmune will screen and validate these targets using its AIM platform. The collaboration will focus on selecting multiple cognate peptides derived from known tumor-associated antigens and neoantigens to rapidly develop new product candidates for clinical trials in patients with cancer in need of lifesaving treatments. "Artificial intelligence is transforming the way the biopharmaceutical industry is approaching target discovery and drug development with the potential to accelerate antigen-specific immunotherapies into the clinic," said Kristi Jones, CEO of NexImmune. "The partnership with Zephyr helps us build a library of novel targets, which can lead to new and more effective cancer therapeutics. We believe that Zephyr's technology is key to helping us identify disease-specific, shared antigens and neoantigens as targets - which can be combined and delivered using the AIM platform - in addition, it may also increase our knowledge of how cancers evolve with the potential to address immune escape mechanisms."

ShowHide Related Items >><<
NEXI Neximmune
$1.80 /

-0.12 (-6.25%)

NEXI Neximmune
$1.80 /

-0.12 (-6.25%)

11/15/21 Raymond James
Neximmune price target lowered to $21 from $30 at Raymond James
03/31/21 Raymond James
Neximmune initiated with an Outperform at Raymond James
NEXI Neximmune
$1.80 /

-0.12 (-6.25%)

Hot Stocks
Neximmune announces melanoma research collaboration with NYU Langone Health » 07:38
03/14/22
03/14
07:38
03/14/22
07:38
NEXI

Neximmune

$1.79 /

-0.095 (-5.04%)

NexImmune announced a…

NexImmune announced a research and evaluation collaboration with The Laura and Isaac Perlmutter Cancer Center, a National Cancer Institute designated Comprehensive Cancer Center and part of NYU Langone Health. The collaboration is centered around NexImmune's artificial antigen presenting cells' ability to expand neoantigen-specific CD8+ T cells in apheresis material provided by melanoma patients. "NexImmune is excited to have Dr. Weber and NYU, one of the nation's leading academic cancer centers, as a partner on this collaboration," said Kristi Jones, Chief Executive Officer of NexImmune. "The AIM technology platform offers a way to explore the expansion of neoantigens not only in melanoma, but a myriad of other cancers. This step will help validate our approach to these novel targets. Collaboration in this field will continue to help us deliver novel and impactful therapies to people suffering with cancer."

ShowHide Related Items >><<
NEXI Neximmune
$1.79 /

-0.095 (-5.04%)

NEXI Neximmune
$1.79 /

-0.095 (-5.04%)

11/15/21 Raymond James
Neximmune price target lowered to $21 from $30 at Raymond James
03/31/21 Raymond James
Neximmune initiated with an Outperform at Raymond James
NEXI Neximmune
$1.79 /

-0.095 (-5.04%)

Syndicate
Neximmune files $200M mixed securities shelf  17:15
03/09/22
03/09
17:15
03/09/22
17:15
NEXI

Neximmune

$2.30 /

+0.12 (+5.50%)

 
ShowHide Related Items >><<
NEXI Neximmune
$2.30 /

+0.12 (+5.50%)

NEXI Neximmune
$2.30 /

+0.12 (+5.50%)

11/15/21 Raymond James
Neximmune price target lowered to $21 from $30 at Raymond James
03/31/21 Raymond James
Neximmune initiated with an Outperform at Raymond James
NEXI Neximmune
$2.30 /

+0.12 (+5.50%)

Earnings
Neximmune reports Q4 EPS (68c), consensus (78c) » 16:36
03/09/22
03/09
16:36
03/09/22
16:36
NEXI

Neximmune

$2.30 /

+0.12 (+5.50%)

Cash, cash equivalents…

Cash, cash equivalents and marketable securities for the company as of December 31, 2021 were $81.8M compared to $5M at December 31, 2020. "2021 was a landmark year for NexImmune and the continued development of our AIM platform technology," said Kristi Jones, CEO. "The funding received from our successful IPO in February of 2021 has allowed us to advance Phase 1/2 clinical trials for NEXI-001 and NEXI-002 and other programs towards the clinic. We plan to provide a clinical update for the NEXI-001 trial in AML during the second half of 2022, as well as provide an update on our expansion cohort in the NEXI-002 trial in relapsed / refractory multiple myeloma. Additionally, we have identified our antigen peptide targets to be included in our first solid tumor IND application for HPV-associated malignancies and expect to file our IND in the first half of this year. We will also be providing an update on AIM INJ direct injectable modality as we continue our IND enabling work. These updates will include preclinical data supporting an IND in oncology and data from our research collaboration with the lab of Professor Kevan Herold at Yale University, which explores the effects of our AIM injectable nanoparticle as a therapeutic for type 1 diabetes. Despite the challenges the biotech market has experienced over the last months, our team continues to execute on all fronts and we remain on track to achieve our key catalysts for 2022."

ShowHide Related Items >><<
NEXI Neximmune
$2.30 /

+0.12 (+5.50%)

NEXI Neximmune
$2.30 /

+0.12 (+5.50%)

11/15/21 Raymond James
Neximmune price target lowered to $21 from $30 at Raymond James
03/31/21 Raymond James
Neximmune initiated with an Outperform at Raymond James
NEXI Neximmune
$2.30 /

+0.12 (+5.50%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.